Today: 3 July 2026
Browse Category

Stock Market 5 January 2026

Viking Therapeutics stock sinks as Novo’s Wegovy pill debut resets obesity-drug pricing

Viking Therapeutics stock sinks as Novo’s Wegovy pill debut resets obesity-drug pricing

New York, January 5, 2026, 14:21 EST — Regular session Shares of Viking Therapeutics slid 9.9% to $31.93 in afternoon trading on Monday as obesity-drug stocks reacted to Novo Nordisk’s U.S. launch of a Wegovy weight-loss pill. Novo’s U.S.-listed shares rose 5.1%, while Eli Lilly fell 3.9% and the SPDR S&P Biotech ETF dropped 2.2%.
5 January 2026
·····
Nvidia stock slips ahead of CES 2026 keynote as Foxconn AI sales jump and Dalio flags bubble risk

Nvidia stock slips ahead of CES 2026 keynote as Foxconn AI sales jump and Dalio flags bubble risk

NEW YORK, Jan 5, 2026, 13:54 EST — Regular session Nvidia shares were down 0.5% on Monday as investors waited for CEO Jensen Huang to headline a CES press conference in Las Vegas at 4 p.m. ET, according to the conference schedule. The chipmaker has faced tougher questions from rivals and even large customers building their own artificial intelligence chips. Reuters
5 January 2026
··
Silver price stock SLV climbs nearly 6% as Venezuela strikes lift safe-haven demand

Silver price stock SLV climbs nearly 6% as Venezuela strikes lift safe-haven demand

New York, Jan 5, 2026, 13:38 EST — Regular session Shares of iShares Silver Trust rose 5.7% to $69.49 in Monday afternoon trading. Spot silver jumped 6% to $76.99 an ounce after U.S. strikes in Venezuela revived demand for safe-haven assets, while markets also weighed expectations for U.S. rate cuts later this year. “The situation around Venezuela has clearly reactivated safe-haven demand,” said Alexander Zumpfe, a precious metals trader at Heraeus Metals Germany. Reuters
5 January 2026
···
Arrowhead Pharmaceuticals stock slides despite Health Canada approval of Redemplo — what investors watch next

Arrowhead Pharmaceuticals stock slides despite Health Canada approval of Redemplo — what investors watch next

New York, Jan 5, 2026, 13:31 EST — Regular session Arrowhead Pharmaceuticals shares were down about 6.9% on Monday after the company said Health Canada approved Redemplo, its triglyceride-lowering drug for familial chylomicronemia syndrome. The stock fell $4.68 to $63.11 after swinging between $60.75 and $70.87. MarketScreener
5 January 2026
···
Chevron stock jumps on Trump Venezuela oil move; traders eye sanctions and Jan. 30 earnings

Chevron stock jumps on Trump Venezuela oil move; traders eye sanctions and Jan. 30 earnings

New York, Jan 5, 2026, 13:39 EST — Regular session Chevron shares rose 5.7% to $164.78 in early afternoon trading on Monday, after swinging between $159.33 and $171.50. ConocoPhillips gained 3.3% and Exxon Mobil added 2.4% as traders rotated into oil names after U.S. forces captured Venezuelan President Nicolás Maduro and investors bet the move could reshape access to the country’s crude. Reuters
5 January 2026
······
1 … 889 890 891 892 893 … 1,613

Stock Market Today

  • AbbVie Jumps 4%, Tops Apogee Buy Price After Earnings Beat
    July 2, 2026, 7:16 PM EDT. AbbVie Inc. finished up 3.99% at $261.07, a new 52-week high. The stock gained nearly $17.8 billion in market cap, putting it well above the $10.9 billion Apogee Therapeutics deal announced June 22. AbbVie closed above targets from RBC Capital, Investing.com and Google Finance. With Q2 earnings set for July 31, the rally puts the spotlight on analyst target hikes. J.P. Morgan and RBC Capital have backed the Apogee buy for its long-term growth, with the company saying the acquisition will add to EPS by 2032. AbbVie outpaced broader markets, which slipped slightly, as investors bet on the drugmaker's deal strategy.
Go toTop